• Ionis completes enrollment in pivotal NEURO-TTRansform study of eplontersen

    1 month ago - By San Diego Biotechnology

    CARLSBAD, Calif.: CARLSBAD, Calif., July 29, 2021 /PRNewswire/ - Ionis Pharmaceuticals, Inc. , the leader in RNA-targeted therapies, today announced it has completed enrollment of NEURO-TTRansform, the company's Phase 3 study of eplontersen, formerly AKCEA-TTR-LRx, for people with hereditary transthyretin-mediated amyloid polyneuropathy. The company has exceeded the enrollment...
    Read more ...